cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.yhwsyq
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Mammalia",
 "HasCoordinate is true",
 "Geometry POLYGON ((-116.8346 35.09052, -116.8318 35.09293, -116.8347 35.09461, -116.8373 35.09243, -116.8346 35.09052))"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006403-251120083545085/datasets/export for details.
DOI: 10.15468/dl.e79z7n
title: Occurrence Download

description: A dataset containing 123 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-797.96899 0.28722,-797.77124 0.28722,-797.77124 0.50121,-797.96899 0.50121,-797.96899 0.28722))",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present",
 "TaxonKey is Anura"
 ]
}

 The dataset includes 123 records from 5 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006404-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7910/dvn/moo2a9
title: Replication Data for: Rebels in the House. Do anti-elitist parties vote differently?

description: Do anti-elitist parties behave differently in parliament than other parties? Existing evidence is inconclusive: some studies suggest that anti-elitist parties do not show a shared voting pattern as this is mainly structured by their substantive left or right-wing ideology. Others suggest that these parties vote against legislation more often. This may reflect their willingness to voice opposition against the sitting government, but also their opposition to the way of doing politics of the established parties. In order to address this substantive issue, this article develops a new method that allows one to look at different explanations of voting concurrently while also taking into account characteristics of the vote. We find that anti-elitist parties do vote differently from other parties but only on legislative votes. Our results also indicate that coalition parties tend to vote united on opposition proposals and that specific ideological dimensions matter only on votes pertaining to that issue. As such, it presents a major step forward not just in the study of how parties operate in parliament but also in the existing methodology to study parliamentary voting behaviour.
DOI: 10.6084/m9.figshare.31120990
title: Supplementary Material for: Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma occurring in spleen of a patient after chemotherapy for lung carcinoma: a case report

description: Introduction: Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm which occurs almost exclusively in the spleen and liver. Although EBV+ inflammatory FDCS is recognized to show indolent behavior, its pathophysiology including the pathogenesis remains unclear. Case Presentation: We present an EBV+ inflammatory FDCS which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA (EBER) in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS. Conclusion: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context with immunosuppression.
DOI: 10.6084/m9.figshare.31120990.v1
title: Supplementary Material for: Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma occurring in spleen of a patient after chemotherapy for lung carcinoma: a case report

description: Introduction: Epstein-Barr virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV+ inflammatory FDCS) is a rare neoplasm which occurs almost exclusively in the spleen and liver. Although EBV+ inflammatory FDCS is recognized to show indolent behavior, its pathophysiology including the pathogenesis remains unclear. Case Presentation: We present an EBV+ inflammatory FDCS which occurred in the spleen of a patient under the follow-up for chemotherapy against lung carcinoma. Sequential CT examinations reveal that a splenic lesion was first detectable 5 years after chemotherapy and has grown for another 3 years to form a mass of 4 cm in diameter. Splenectomy was performed. Histologically, a well circumscribed lesion in the spleen exhibited the significant infiltration of lymphocytes and plasma cells in the background of hyalinized fibrous tissue, and large oval-shaped cells were intermingled with lymphocytes and plasma cells. Large oval-shaped cells were found to express CD21 and CD23, and they were shown to be positive for EBV-encoded small RNA (EBER) in situ hybridization. Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS. Conclusion: The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context with immunosuppression.
DOI: 10.6084/m9.figshare.31120999
title: Supplementary Material for: IPSS, IPSS-R and IPSS-M had no identical prognostic power depending on treatment in myelodysplastic syndromes

description: Introduction
The Revised International Prognostic Scoring System (IPSS-R) has long been the standard prognostic tool in the management of myelodysplastic syndromes (MDS). Recently, a new clinical-molecular prognostic model, the IPSS-M, was introduced. This model integrates MDS-related gene mutations and offers improved accuracy and precision in predicting patient outcomes and survival. In this study, we compare the prognostic value and predictive capacity of these prognostic scores across different treatment groups.
Methods
IPSS, IPSS-R, and IPSS-M scores were calculated at diagnosis for all eligible MDS patients in this cohort. Sankey diagrams were generated to visually compare the risk stratification across the three scoring systems.
Results
A total of 394 patients were included in this retrospective analysis. During the course of the disease, 59.1% required treatment, with 38.1% (150 patients) receiving erythropoiesis-stimulating agents (ESA) and 19.0% (75 patients) treated with hypomethylating agents (HMA). The IPSS-M was calculated for 281 patients and reclassified 41.9% of cases: 20.3% (n=57) were upstaged and 21.7% (n=61) were downstaged. All three scoring systems demonstrated significant stratification of overall survival (OS) in the global cohort (p&lt;0.001 for IPSS, IPSS-R, and IPSS-M). Notably, IPSS failed to predict OS in patients treated with azacitidine, and none of the scores successfully predicted OS in patients treated with ESA.
Conclusion
The IPSS-M effectively reclassified 41.9% of patients, upstaging 20.2% and downstaging 21.7%. However, our analysis found that none of the prognostic scores effectively predicted outcomes for ESA-treated patients. Further studies are needed to assess whether the predictive value of these scoring systems is influenced by the specific treatment modalities used.
DOI: 10.6084/m9.figshare.31120999.v1
title: Supplementary Material for: IPSS, IPSS-R and IPSS-M had no identical prognostic power depending on treatment in myelodysplastic syndromes

description: Introduction
The Revised International Prognostic Scoring System (IPSS-R) has long been the standard prognostic tool in the management of myelodysplastic syndromes (MDS). Recently, a new clinical-molecular prognostic model, the IPSS-M, was introduced. This model integrates MDS-related gene mutations and offers improved accuracy and precision in predicting patient outcomes and survival. In this study, we compare the prognostic value and predictive capacity of these prognostic scores across different treatment groups.
Methods
IPSS, IPSS-R, and IPSS-M scores were calculated at diagnosis for all eligible MDS patients in this cohort. Sankey diagrams were generated to visually compare the risk stratification across the three scoring systems.
Results
A total of 394 patients were included in this retrospective analysis. During the course of the disease, 59.1% required treatment, with 38.1% (150 patients) receiving erythropoiesis-stimulating agents (ESA) and 19.0% (75 patients) treated with hypomethylating agents (HMA). The IPSS-M was calculated for 281 patients and reclassified 41.9% of cases: 20.3% (n=57) were upstaged and 21.7% (n=61) were downstaged. All three scoring systems demonstrated significant stratification of overall survival (OS) in the global cohort (p&lt;0.001 for IPSS, IPSS-R, and IPSS-M). Notably, IPSS failed to predict OS in patients treated with azacitidine, and none of the scores successfully predicted OS in patients treated with ESA.
Conclusion
The IPSS-M effectively reclassified 41.9% of patients, upstaging 20.2% and downstaging 21.7%. However, our analysis found that none of the prognostic scores effectively predicted outcomes for ESA-treated patients. Further studies are needed to assess whether the predictive value of these scoring systems is influenced by the specific treatment modalities used.
DOI: 10.6084/m9.figshare.31121005
title: Supplementary Material for: Pulmonary Lobar Torsion Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves: A Case Report

description: Introduction: Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) is an effective and minimally invasive alternative to lung volume reduction surgery for some patients with severe emphysema. While generally well-tolerated, it may lead to rare but serious complications. Pulmonary lobar torsion and secondary infarction is a known postoperative complication after thoracic surgery but has not been previously reported following BLVR.

Case presentation: A 70-year-old woman with chronic obstructive pulmonary disease (COPD) underwent EBV placement in the right upper lobe, with a good lung function and clinical improvement. Fifteen months after placement, she presented with epigastric pain, haemoptysis, and respiratory distress. Imaging revealed a torsion of the right upper lobe, initially misinterpreted as pneumonia, which necessitated an urgent thoracotomy and lobectomy. Intraoperative and histopathological findings were compatible with the diagnosis of lobar torsion with ischemic necrosis.

Conclusion: This case presents the first reported pulmonary lobar torsion following EBV treatment. The clinical presentation can be nonspecific or with misleading symptoms, potentially leading to diagnostic delays. Clinicians should be aware of such complication in patients with previous BLVR presenting with new or unexplained clinical findings. Imaging and early surgical intervention are critical to prevent life- threatening complications.
DOI: 10.6084/m9.figshare.31121005.v1
title: Supplementary Material for: Pulmonary Lobar Torsion Following Bronchoscopic Lung Volume Reduction with Endobronchial Valves: A Case Report

description: Introduction: Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBVs) is an effective and minimally invasive alternative to lung volume reduction surgery for some patients with severe emphysema. While generally well-tolerated, it may lead to rare but serious complications. Pulmonary lobar torsion and secondary infarction is a known postoperative complication after thoracic surgery but has not been previously reported following BLVR.

Case presentation: A 70-year-old woman with chronic obstructive pulmonary disease (COPD) underwent EBV placement in the right upper lobe, with a good lung function and clinical improvement. Fifteen months after placement, she presented with epigastric pain, haemoptysis, and respiratory distress. Imaging revealed a torsion of the right upper lobe, initially misinterpreted as pneumonia, which necessitated an urgent thoracotomy and lobectomy. Intraoperative and histopathological findings were compatible with the diagnosis of lobar torsion with ischemic necrosis.

Conclusion: This case presents the first reported pulmonary lobar torsion following EBV treatment. The clinical presentation can be nonspecific or with misleading symptoms, potentially leading to diagnostic delays. Clinicians should be aware of such complication in patients with previous BLVR presenting with new or unexplained clinical findings. Imaging and early surgical intervention are critical to prevent life- threatening complications.
DOI: 10.15468/dl.zb6bxr
title: Occurrence Download

description: A dataset containing 115 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is Hong Kong",
 "TaxonKey is Vespa ducalis"
 ]
}

 The dataset includes 115 records from 2 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004214-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.31121011
title: Supplementary Material for: Anxiety trajectories during electroconvulsive therapy and their role in predicting depression treatment response: towards personalized therapy

description: Introduction: Current predictors of electroconvulsive therapy (ECT) effects rely on static measures. The prognostic value of anxiety evolution during ECT remains unestablished, which impedes personalized treatment. This study aims to investigate the dynamic evolution of anxiety during ECT and its predictive role in treatment effects. Methods: We collected 1,053 data points from 117 patients with depression who were undergoing ECT, measuring both the Hamilton Anxiety Rating Scale (HAMA) and the 17-item Hamilton Depression Rating Scale (HAMD-17) at baseline and at each of the first eight ECT sessions. K-means longitudinal (KML) clustering identified anxiety evolution patterns, while linear mixed-effects modeling (LMM) and survival analysis were used to assess associations with treatment outcomes. Results: Three distinct anxiety trajectory phenotypes were identified: Rapid Anxiety Remitters (Cluster A: 47%), Gradual Anxiety Improvers (Cluster B: 41%), and Anxiety Non-Remitters (Cluster C: 12%). LMM analysis demonstrated significantly greater HAMD-17 reduction slopes in Cluster A (β = -1.32, p = 0.003) and Cluster B (β = -1.15, p = 0.007) compared to Cluster C. Kaplan-Meier analysis revealed a hierarchical response advantage (Cluster A &gt; B &gt; C; Log-Rank χ² = 32.15, p &lt; 0.001). Multivariable Cox regression confirmed the superior predictive value of trajectories over baseline HAMA: Rapid Anxiety Remitters showed a 19.77-fold higher response likelihood than Anxiety Non-Remitters (95%CI 8.21-47.63), compared to only a 4% increased probability per HAMA point (hazard ratios = 1.04). Conclusion: Dynamic anxiety trajectories are effective biomarkers for ECT response, offering enhanced predictive value over baseline HAMA scores and enabling personalized treatment strategies for depression.
DOI: 10.6084/m9.figshare.31121011.v1
title: Supplementary Material for: Anxiety trajectories during electroconvulsive therapy and their role in predicting depression treatment response: towards personalized therapy

description: Introduction: Current predictors of electroconvulsive therapy (ECT) effects rely on static measures. The prognostic value of anxiety evolution during ECT remains unestablished, which impedes personalized treatment. This study aims to investigate the dynamic evolution of anxiety during ECT and its predictive role in treatment effects. Methods: We collected 1,053 data points from 117 patients with depression who were undergoing ECT, measuring both the Hamilton Anxiety Rating Scale (HAMA) and the 17-item Hamilton Depression Rating Scale (HAMD-17) at baseline and at each of the first eight ECT sessions. K-means longitudinal (KML) clustering identified anxiety evolution patterns, while linear mixed-effects modeling (LMM) and survival analysis were used to assess associations with treatment outcomes. Results: Three distinct anxiety trajectory phenotypes were identified: Rapid Anxiety Remitters (Cluster A: 47%), Gradual Anxiety Improvers (Cluster B: 41%), and Anxiety Non-Remitters (Cluster C: 12%). LMM analysis demonstrated significantly greater HAMD-17 reduction slopes in Cluster A (β = -1.32, p = 0.003) and Cluster B (β = -1.15, p = 0.007) compared to Cluster C. Kaplan-Meier analysis revealed a hierarchical response advantage (Cluster A &gt; B &gt; C; Log-Rank χ² = 32.15, p &lt; 0.001). Multivariable Cox regression confirmed the superior predictive value of trajectories over baseline HAMA: Rapid Anxiety Remitters showed a 19.77-fold higher response likelihood than Anxiety Non-Remitters (95%CI 8.21-47.63), compared to only a 4% increased probability per HAMA point (hazard ratios = 1.04). Conclusion: Dynamic anxiety trajectories are effective biomarkers for ECT response, offering enhanced predictive value over baseline HAMA scores and enabling personalized treatment strategies for depression.
DOI: 10.6084/m9.figshare.31121022
title: Additional file 2 of Estimating the prevalence of Echinococcus spp. in a Tibetan fox (Vulpes ferrilata) population on the eastern Tibetan Plateau

description: Additional file 2.
DOI: 10.6084/m9.figshare.31121022.v1
title: Additional file 2 of Estimating the prevalence of Echinococcus spp. in a Tibetan fox (Vulpes ferrilata) population on the eastern Tibetan Plateau

description: Additional file 2.
DOI: 10.15468/dl.kq2dty
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{"type":"and","predicates":[{"type":"within","geometry":"POLYGON ((96.158 4.906154, 96.087481 4.900584, 96.018702 4.884011, 95.95335799999999 4.856844, 95.893063 4.819752, 95.83930100000001 4.773651, 95.793397 4.719678, 95.75648 4.659163, 95.72945900000001 4.593598, 95.71299500000001 4.524598, 95.707491 4.453862, 95.71308000000001 4.383133, 95.72962 4.314152, 95.756703 4.248616, 95.79365900000001 4.188139, 95.83957599999999 4.134208, 95.893325 4.088149, 95.953581 4.051095, 96.018863 4.023958, 96.087566 4.007404, 96.158 4.00184, 96.22843399999999 4.007404, 96.29713700000001 4.023958, 96.362419 4.051095, 96.422675 4.088149, 96.47642399999999 4.134208, 96.522341 4.188139, 96.559297 4.248616, 96.58638000000001 4.314152, 96.60292 4.383133, 96.608509 4.453862, 96.603005 4.524598, 96.586541 4.593598, 96.55952000000001 4.659163, 96.522603 4.719678, 96.476699 4.773651, 96.422937 4.819752, 96.36264199999999 4.856844, 96.297298 4.884011, 96.22851900000001 4.900584, 96.158 4.906154))"},{"type":"equals","key":"CLASS_KEY","value":"212","matchCase":false},{"type":"greaterThanOrEquals","key":"YEAR","value":"2015","matchCase":false},{"type":"not","predicate":{"type":"in","key":"BASIS_OF_RECORD","values":["MATERIAL_CITATION","MATERIAL_SAMPLE","PRESERVED_SPECIMEN"],"matchCase":false}},{"type":"lessThanOrEquals","key":"COORDINATE_UNCERTAINTY_IN_METERS","value":"10000","matchCase":false},{"type":"equals","key":"LICENSE","value":"CC BY 4.0","matchCase":false}]}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0004215-260120142942310/datasets/export for details.
DOI: 10.6084/m9.figshare.31121044
title: Additional file 3 of Increased prolactin levels in pregnancy affect colorectal cancer aggressiveness

description: Additional file 3. Data S1 – HT29 protein expression quantification after treatment with pregnancy-level PRL concentrations. Data S2 – COLO320 protein expression quantification after treatment with pregnancy-level PRL concentrations. Data S3 – Cell viability quantification of non-treated and PRL-treated HT29 cells under FSS after soluble TRAIL, and liposomal TRAIL treatments.
DOI: 10.6084/m9.figshare.31121044.v1
title: Additional file 3 of Increased prolactin levels in pregnancy affect colorectal cancer aggressiveness

description: Additional file 3. Data S1 – HT29 protein expression quantification after treatment with pregnancy-level PRL concentrations. Data S2 – COLO320 protein expression quantification after treatment with pregnancy-level PRL concentrations. Data S3 – Cell viability quantification of non-treated and PRL-treated HT29 cells under FSS after soluble TRAIL, and liposomal TRAIL treatments.
DOI: 10.6084/m9.figshare.31121064
title: Additional file 2 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.31121064.v1
title: Additional file 2 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 2.
DOI: 10.6084/m9.figshare.31121067
title: Additional file 3 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 3.
DOI: 10.6084/m9.figshare.31121067.v1
title: Additional file 3 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 3.
DOI: 10.6084/m9.figshare.31121070
title: Additional file 4 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 4.
DOI: 10.6084/m9.figshare.31121070.v1
title: Additional file 4 of Genomic resources for Australian alfalfa (Medicago sativa L.) genomics: reformatted reference genome, annotated variants, gene presence-absence and diversity analysis from genome re-sequencing

description: Supplementary Material 4.
DOI: 10.6084/m9.figshare.31121065
title: Additional file 5 of Building consensus: construction of a juvenile and adult scRNA-seq meta-atlas for dataset comparisons and harmonizing transcriptomic definitions of enteric neuron subtypes

description: Supplementary Material 5. Supplementary Table 1. May-Zhang2021_10x_6wks_MouseColDuodIle_SCTv2Integrated_FAM.
DOI: 10.6084/m9.figshare.31121065.v1
title: Additional file 5 of Building consensus: construction of a juvenile and adult scRNA-seq meta-atlas for dataset comparisons and harmonizing transcriptomic definitions of enteric neuron subtypes

description: Supplementary Material 5. Supplementary Table 1. May-Zhang2021_10x_6wks_MouseColDuodIle_SCTv2Integrated_FAM.
DOI: 10.6084/m9.figshare.31121068
title: Additional file 6 of Building consensus: construction of a juvenile and adult scRNA-seq meta-atlas for dataset comparisons and harmonizing transcriptomic definitions of enteric neuron subtypes

description: Supplementary Material 6. Supplementary Table 2. May-Zhang2021_InDrop_6wks_MouseColDuodIle_SCTv2Integrated_FAM.
DOI: 10.6084/m9.figshare.31121068.v1
title: Additional file 6 of Building consensus: construction of a juvenile and adult scRNA-seq meta-atlas for dataset comparisons and harmonizing transcriptomic definitions of enteric neuron subtypes

description: Supplementary Material 6. Supplementary Table 2. May-Zhang2021_InDrop_6wks_MouseColDuodIle_SCTv2Integrated_FAM.